Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle?
Genmab A/S (NASDAQ:GMAB) boosted its full-year 2026 revenue guidance to a range of $4.325 billion to $4.525 billion, up from its previous outlook of $4.065 billion to $4.395 billion.







